Merck & Co., Inc: Diabetes Mellitus, Type 2 trials
The registry lists 181 Diabetes Mellitus, Type 2 studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 150 have results posted.
Phase 1 55Phase 2 21Phase 3 86Phase 4 6No phase 13(a study in two phases counts in both)
Studies
Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)CompletedNCT04029480Phase 3Results posted
- Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)CompletedNCT03170544Phase 1Results posted
- Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)CompletedNCT03095651Phase 1Results posted
- Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)CompletedNCT02906709Phase 4Results posted
- A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)CompletedNCT02791490Phase 3Results posted
- Randomized Sitagliptin Withdrawal Study (MK-0431-845)CompletedNCT02738879Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)CompletedNCT02630706Phase 3Results posted
- Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)CompletedNCT02577016Phase 3Results posted
- Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)CompletedNCT02577003Phase 3Results posted
- Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)CompletedNCT02564211Phase 3Results posted
- A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)CompletedNCT02532855Phase 3Results posted
- A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)TerminatedNCT02492763Phase 2Results posted
- A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)CompletedNCT02411929Phase 1Results posted
- Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)CompletedNCT02318693Phase 4Results posted
- Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)CompletedNCT02226003Phase 3Results posted
- Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)CompletedNCT02115347Phase 1Results posted
- Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)CompletedNCT02099110Phase 3Results posted
- The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)CompletedNCT02059187Phase 3Results posted
- A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)CompletedNCT02055547Phase 1Results posted
- Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)CompletedNCT02036515Phase 3Results posted
- A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).CompletedNCT02033889Phase 3Results posted
- A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)CompletedNCT02004886Phase 2Results posted
- Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)CompletedNCT01999218Phase 3Results posted
- Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)CompletedNCT01986881Phase 3Results posted
- A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)CompletedNCT01986855Phase 3Results posted
- Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)CompletedNCT01971554Phase 1Results posted
- A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)CompletedNCT01958671Phase 3Results posted
- Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)CompletedNCT01948986Phase 1Results posted
- A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)TerminatedNCT01863667Phase 3Results posted
- Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)CompletedNCT01841697Phase 3Results posted
- A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)CompletedNCT01814748Phase 3Results posted
- A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)CompletedNCT01767688Phase 1Results posted
- A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)CompletedNCT01760447Phase 3Results posted
- A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)CompletedNCT01755156Phase 3Results posted
- A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)CompletedNCT01717313Phase 3Results posted
- A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)CompletedNCT01709305Phase 4Results posted
- Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)CompletedNCT01704261Phase 3Results posted
- Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)CompletedNCT01703221Phase 3Results posted
- A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)TerminatedNCT01703208Phase 3Results posted
- A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)CompletedNCT01702298Phase 3Results posted
- A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)CompletedNCT01698775Phase 3Results posted
- Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)CompletedNCT01697592Phase 3Results posted
- A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)CompletedNCT01682759Phase 3Results posted
- A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)TerminatedNCT01678820Phase 3Results posted
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)CompletedNCT01640873Phase 1Results posted
- Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)CompletedNCT01614769Phase 1Results posted
- A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)CompletedNCT01590797Phase 3Results posted
- A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)CompletedNCT01590771Phase 3Results posted
- A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)CompletedNCT01582308Phase 1Results posted
- A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)CompletedNCT01557504Phase 1Results posted
- Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)CompletedNCT01545388Phase 3Results posted
- Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)CompletedNCT01537120Phase 1Results posted
- Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)CompletedNCT01485614Phase 3Results posted
- A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)TerminatedNCT01477853Phase 3Results posted
- Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes (MK-0000-113)CompletedNCT01472341Results posted
- Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)CompletedNCT01462266Phase 3Results posted
- A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)CompletedNCT01409213Results posted
- A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)CompletedNCT01407276Phase 1Results posted
- Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)CompletedNCT01373450Phase 1Results posted
- A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)TerminatedNCT01357148Results posted
- An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)CompletedNCT01357135Results posted
- A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)CompletedNCT01354990Results posted
- Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)CompletedNCT01340768Phase 3Results posted
- Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)CompletedNCT01296412Phase 3Results posted
- Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-401)CompletedNCT01285076Results posted
- Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-402)CompletedNCT01278485Results posted
- A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)CompletedNCT01217073Phase 2Results posted
- Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)CompletedNCT01189890Phase 3Results posted
- Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)CompletedNCT01177384Phase 3Results posted
- Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)CompletedNCT01131182Phase 4Results posted
- Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)CompletedNCT01106287Phase 1Results posted
- Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)CompletedNCT01096667Phase 2Results posted
- Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)CompletedNCT01093794Phase 1Results posted
- Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)CompletedNCT01088711Phase 1Results posted
- Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)CompletedNCT01076088Phase 3Results posted
- A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)CompletedNCT01076075Phase 3Results posted
- Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)CompletedNCT01065766Results posted
- Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)CompletedNCT01059825Phase 2Results posted
- Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)CompletedNCT01054300Phase 1Results posted
- A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)CompletedNCT01034111Phase 3Results posted
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)CompletedNCT01028391Phase 3Results posted
- Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)CompletedNCT00993187Phase 4Results posted
- A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)CompletedNCT00979459Phase 1Results posted
- Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)CompletedNCT00972322Phase 1Results posted
- Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)CompletedNCT00944450Phase 1Results posted
- Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)CompletedNCT00929201Phase 1Results posted
- A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED)CompletedNCT00912002Phase 1Results posted
- The OBSTACLE Hypoglycemia Study (MK-0000-158)CompletedNCT00907881Results posted
- A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)CompletedNCT00902161Phase 1Results posted
- A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)CompletedNCT00888238Phase 1Results posted
- Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)CompletedNCT00885352Phase 3Results posted
- Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)CompletedNCT00875394Phase 3Results posted
- A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)CompletedNCT00873821Phase 1Results posted
- A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)TerminatedNCT00868790Phase 2Results posted
- A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)TerminatedNCT00846391Phase 2Results posted
- MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)CompletedNCT00837577Phase 3Results posted
- The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)TerminatedNCT00832624Phase 4Results posted
- A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02)TerminatedNCT00830791Phase 1Results posted
- A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)CompletedNCT00830076Phase 1Results posted
- A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)CompletedNCT00824616Phase 2Results posted